Background: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, with surgical resection offering the best chance of survival. However, many patients are not eligible for surgery. Neoadjuvant therapy (NAT) offers the potential to downsize borderline resectable (BR) and locally advanced (LA) PDAC, making resection feasible. The study aims to asses body composition changes during NAT, in particular, the progression of sarcopenia, and how this impact outcomes in these patients.